$1.51
0.00% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
CA59935V1076
Symbol
MIST
Sector
Industry

Milestone Pharmaceuticals, Inc. Stock price

$1.51
+0.01 0.67% 1M
-0.30 16.57% 6M
-0.16 9.58% YTD
-1.49 49.67% 1Y
-4.14 73.27% 3Y
-15.29 91.01% 5Y
-13.49 89.93% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
+0.00 0.00%
ISIN
CA59935V1076
Symbol
MIST
Sector
Industry

Key metrics

Market capitalization $80.44m
Enterprise Value $50.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.52
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-49.59m
Free Cash Flow (TTM) Free Cash Flow $-36.39m
Cash position $83.25m
EPS (TTM) EPS $-1.11
P/E forward negative
Short interest 0.72%
Show more

Is Milestone Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Milestone Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Milestone Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.61 0.61
-
-
-0.61 -0.61
-
-
- Selling and Administrative Expenses 30 30
11% 11%
-
- Research and Development Expense 19 19
52% 52%
-
-49 -49
19% 19%
-
- Depreciation and Amortization 0.61 0.61
27% 27%
-
EBIT (Operating Income) EBIT -50 -50
19% 19%
-
Net Profit -48 -48
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Milestone Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Milestone Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
21 days ago
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from a multi-center, randomized, double-blind, placebo-controlled...
Neutral
GlobeNewsWire
23 days ago
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024.
Neutral
GlobeNewsWire
about 2 months ago
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board Directors MONTREAL and CHARLOTTE, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the second quarter e...
More Milestone Pharmaceuticals, Inc. News

Company Profile

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.

Head office Canada
CEO Joseph Oliveto
Employees 47
Founded 2003
Website www.milestonepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today